Cytokinetics, Incorporated (CYTK)

Market Cap	7.65B +73.2%
Revenue (ttm)	88.04M +376.6%
Net Income	-784.96M
EPS	-6.54
Shares Out	124.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,259,116
Open	65.41
Previous Close	65.32
Day's Range	61.15 - 65.87
52-Week Range	29.31 - 70.98
Beta	0.48
Analysts	Strong Buy
Price Target	89.26 (+44.9%)
Earnings Date	May 5, 2026

About CYTK

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in h...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 29, 2004
• Employees: 673
• Stock Exchange: NASDAQ
• Ticker Symbol: CYTK
• Website: https://www.cytokinetics.com

Financial Performance

In 2025, Cytokinetics's revenue was $88.04 million, an increase of 376.56% compared to the previous year's $18.47 million. Losses were -$784.96 million, 33.2% more than in 2024.

Analyst Summary

According to 19 analysts, the average rating for CYTK stock is "Strong Buy." The 12-month stock price target is $89.26, which is an increase of 44.90% from the latest price.

Price Target

$89.26

(44.90% upside)

Analyst Consensus: Strong Buy